For millions of breast cancer survivors, the conclusion of medical treatment—surgery, chemotherapy, or radiation—is meant to mark a return to normalcy. Yet, for a significant portion of these individuals, the most challenging hurdles are not physical scars, but internal, invisible ones. Long after the cancer has been declared in remission, many survivors grapple with persistent cognitive deficits: memory lapses, an inability to concentrate, and a deep-seated, unshakable exhaustion that can make even the most mundane daily tasks feel insurmountable. These symptoms, often colloquially termed "chemo brain" or "brain fog," can endure for years, fundamentally altering a survivor’s quality of life.
Now, a team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has unveiled promising, albeit preliminary, evidence that a naturally occurring molecule known as oxaloacetate may offer a new path toward symptom relief. The study, published in the journal JCO Oncology Advances, suggests that this supplement could potentially address the underlying biological mechanisms that lead to long-term cognitive impairment and fatigue in those who have survived breast cancer.
The Biological Complexity of ‘Brain Fog’
To understand why this supplement might be effective, it is necessary to first understand the condition it aims to treat. Cognitive impairment following cancer is a multifaceted issue that affects an estimated 15% to 25% of breast cancer survivors. While the term "chemo brain" suggests that chemotherapy is the sole culprit, the reality is far more complex. Modern oncology research recognizes that cognitive decline is often the result of an intricate web of overlapping influences.
The biological disruption can be triggered by the cancer itself, as well as the various therapies required to fight it, including endocrine therapies and chemotherapy. Furthermore, systemic inflammation, hormonal shifts, and various behavioral and biological stressors all interact to disrupt normal brain function. Because these causes are so diverse and interconnected, finding a universal treatment has proven notoriously difficult.
Researchers have increasingly turned their attention to the link between inflammation, cellular energy production, and brain chemistry. The hypothesis is that chronic inflammation—often spurred by the body’s response to cancer and its treatments—can interfere with glutamate signaling. Glutamate acts as a vital neurotransmitter, facilitating communication between nerve cells. When this signaling process is disrupted, and when the brain’s cellular machinery struggles to produce and use energy efficiently, the result is the mental exhaustion and cognitive fragmentation that survivors describe as "brain fog."
Oxaloacetate, a molecule already present within the human body, occupies a unique position in this biological puzzle. It is a fundamental participant in the Krebs cycle, the process by which cells generate energy. Crucially, it is also involved in the regulation of glutamate. By investigating whether supplemental oxaloacetate could bolster these two critical processes, the UCLA team sought to determine if they could mitigate the debilitating symptoms of cognitive impairment and persistent fatigue.
Investigating the Efficacy of Oxaloacetate
The UCLA research team conducted a phase II clinical trial to test this hypothesis, enrolling 18 women who had been diagnosed with early-stage breast cancer between one and five years prior. At the time of enrollment, every participant reported suffering from significant, ongoing cognitive difficulties. The group was representative of the broader survivor population, with an average age of 50. Most participants had undergone chemotherapy, and nearly 90% were continuing to receive endocrine therapy, which is standard practice to prevent cancer recurrence but is also known to contribute to cognitive side effects.
The trial protocol was straightforward: participants were instructed to take 500 milligrams of oxaloacetate twice daily for a period of eight weeks. Throughout this timeframe, the researchers utilized a comprehensive set of metrics to monitor progress. These included self-reported questionnaires that tracked the participants’ subjective experience of "brain fog," as well as standardized clinical tests designed to measure objective markers of memory, attention, processing speed, and executive function.
Executive function is a critical component of daily life, encompassing the cognitive abilities required to organize complex activities, maintain sustained focus, develop and execute plans, and manage multifaceted tasks. In addition to these cognitive markers, the study evaluated broader health indicators, including sleep quality, anxiety, depression, physical health, and general mental well-being. Throughout the study, the medical team remained vigilant, monitoring the participants for any potential adverse side effects associated with the supplementation.
Significant Improvements in Cognitive Function
The outcomes of the eight-week trial were notably positive. Out of the 18 women who began the study, 16 completed the full duration of the supplementation. Every single participant who finished the regimen reported a meaningful improvement in her cognitive symptoms.
The most dramatic changes were observed in the participants’ self-reported cognitive impairment scores. Prior to the commencement of the supplement, the group’s average score was 29.1, a figure reflecting significant impairment. By the end of the eight-week study, that average had surged to 55.5. Perhaps most encouragingly, this shift moved the group’s average performance from a range of cognitive impairment into a range considered "normal" by standard assessment metrics.
The benefits were not merely anecdotal or delayed; signs of improvement were observable as early as four weeks into the study, and these improvements generally intensified as the treatment continued. The positive effects appeared to ripple outward from cognitive clarity to physical vitality. Participants reported a significant reduction in the type of mental exhaustion that makes physical movement or daily activity feel overwhelming, and they described tangible improvements in their physical functional capacity.
Furthermore, the standardized cognitive tests corroborated these self-reports. The researchers recorded objective gains in processing speed and executive function, suggesting that the supplement may have helped the brain perform at a higher level, rather than simply making the participants feel as though they were thinking more clearly.
Dr. Patricia Ganz, the study’s first author and a distinguished professor of medicine at UCLA’s David Geffen School of Medicine and UCLA Fielding School of Public Health, emphasized the importance of these findings. "Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it," she noted.
Moving Toward Larger Clinical Trials
Despite the promising nature of the data, the researchers remain cautious. Because the study was a phase II trial with a small cohort, it lacks the statistical power of a large-scale, randomized, placebo-controlled trial. Without a control group, it is impossible to definitively prove that the oxaloacetate was the direct cause of the improvements, rather than a placebo effect or other confounding variables.
Safety, however, was a bright spot in the trial. Oxaloacetate was found to be generally well tolerated. While there were reports of digestive issues—including bloating, indigestion, nausea, diarrhea, and constipation—these were the most common side effects, and only two participants found the gastrointestinal symptoms severe enough to discontinue the supplement. No serious adverse events were documented during the eight-week period.
Looking ahead, the UCLA team is committed to rigorous validation of these initial results. They are currently preparing for a randomized, placebo-controlled phase II clinical trial, which is expected to begin enrolling breast cancer survivors in late 2026. This larger study will be essential in determining whether oxaloacetate provides genuine, measurable benefits that surpass those of a placebo.
Simultaneously, the team is conducting preclinical research using animal models. By studying the impact of oxaloacetate on mice, researchers hope to gain a deeper, more granular understanding of the biological mechanisms at play. These experiments, which include their own placebo-controlled components, aim to clarify how the molecule affects energy production and cellular health in both the brain and the body, potentially confirming the link between physical function and cognitive performance observed in the human trial.
This research, which received support from the National Cancer Institute and the Breast Cancer Research Foundation, represents a vital step toward filling a major gap in survivorship care. As Dr. Ganz stated, "These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment." For survivors who have long lived with the haze of "chemo brain," the promise of a potential, evidence-based solution is a significant, hopeful development.

